SEC Tracker
Get the app
BVS · XBRL financial data

Bioventus financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BVS's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 31, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Dec 31, 2025Mar 28, 2026Jun 27, 2026Sep 26, 2026
Revenue from contracts with customers135,423*129,457151,217138,964153,642*123,876147,660138,651157,900*132,089153,208142,442
Cost of goods and services sold49,122*41,07747,57845,41350,986*40,82045,57044,42249,118*41,32047,54245,314
Gross profit86,301*88,380103,63993,551102,656*83,056102,09094,229108,782*90,769105,66697,128
Research and development3,262*2,5973,9883,8083,246*3,0113,1722,9233,007*2,4673,1733,435
Selling, general and administrative78,357*78,40694,78581,09086,613*73,50279,11078,65782,757*78,32582,74082,945
Operating income (loss)1,165*5,327(29,368)4,0747,988*4,86918,36811,25219,486*8,41619,1279,700
Other income (expense)709*(63)(159)6261,241*(777)(561)(79)(37)*427249216
Income tax expense (benefit)(750)*907(7,339)589550*(95)1,041664(3,175)*571(20,897)(701)
Net income (loss)(6,096)*(4,570)(23,992)(4,824)(156)*(2,637)7,4593,15514,755*3,11333,4415,987
Earnings per share, basic USD per share(0.10)*(0.07)(0.37)(0.07)0.00*(0.04)0.110.050.22*0.050.490.09
Earnings per share, diluted USD per share(0.10)*(0.07)(0.37)(0.07)0.00*(0.04)0.110.050.20*0.040.470.08
Weighted average shares, basic thousands of shares63,085*63,38064,05765,25865,452*66,00966,50066,92567,019*67,29667,86968,377
Weighted average shares, diluted thousands of shares63,085*63,38064,05765,25865,452*66,00968,53768,83872,043*70,00870,83872,493

Balance sheet

CSV

Fiscal quarters (BVS's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 31, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Dec 31, 2025Mar 28, 2026Jun 27, 2026Sep 26, 2026
Cash and cash equivalents36,96425,17331,99443,07441,58222,80232,91042,16451,23835,84629,45730,709
Accounts receivable122,789125,541137,305121,925127,393118,082132,367130,404128,303120,525138,406138,228
Inventory91,33397,00587,60690,03292,47594,04596,46596,27382,23683,18779,80783,096
Prepaid and other current assets16,91318,18423,57016,92314,16014,43813,46112,06011,06510,2559,85713,509
Total current assets267,999265,903308,883298,688275,610249,367275,203280,901272,842249,813257,527265,542
Right-of-use asset13,35312,46210,3669,7796,5066,6316,2255,8305,1224,6874,2253,756
Goodwill7,4627,4627,4627,4627,4627,4627,4627,4627,4627,4627,4627,462
Total assets810,910794,238792,173769,492727,956691,414706,788701,593683,559650,539673,346673,430
Accounts payable23,03819,09924,43716,84923,69019,19724,24526,64910,92824,05020,19625,787
Accrued liabilities119,795113,605139,978128,697135,879103,283113,666119,446130,242101,135109,361109,027
Current portion of long-term debt27,84835,81138,56638,56627,33937,33943,35811,25015,00018,75018,75018,750
Total current liabilities175,497173,321231,463211,492210,398174,751185,680161,752160,380148,095152,451157,704
Long-term debt366,998355,430344,716345,021308,288308,593297,880311,334278,951253,326229,702211,077
Lease liability, non-current10,5739,6718,4697,7906,9406,4255,8245,2144,4563,7032,9252,211
Total liabilities589,792576,806603,111582,659542,352505,935505,489494,338455,112416,274395,934381,556
Accumulated deficit(321,536)(326,106)(350,098)(354,922)(355,078)(360,298)(352,839)(349,684)(334,929)(331,816)(298,375)(292,388)
Total stockholders' equity173,591171,276150,935148,738147,940148,144161,242166,096184,105188,901228,306240,499
Total liabilities and equity810,910794,238792,173769,492727,956691,414706,788701,593683,559650,539673,346673,430

Cash flows

CSV

Fiscal quarters (BVS's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 30, 2024Jun 29, 2024Sep 28, 2024Dec 31, 2024Mar 29, 2025Jun 28, 2025Sep 27, 2025Dec 31, 2025Mar 28, 2026Jun 27, 2026Sep 26, 2026
Net income (loss)(6,096)*(4,570)(23,992)(4,824)(156)*(2,637)7,4593,15514,755*3,11333,4415,987
Stock-based compensation1,775*2,5913,672*2,064*1,731*2,4143,643*3,176*3,440*3,2645,041*4,756*
Depreciation and amortization12,465*11,78513,090*12,275*12,405*11,86512,049*11,403*11,694*11,20510,945*10,315*
Net cash from operating activities10,374*(6,005)15,162*10,316*19,322*(19,331)25,938*30,098*37,968*8,93419,873*20,658*
Purchases of property and equipment369*29177*64*574*826683*473*580*574960*334*
Net cash from investing activities(591)*(1,000)(77)*(64)*24,104*(826)(1,369)*(473)*(580)*(574)(2,460)*(1,834)*
Proceeds from issuing common stock158*177609*553*1,103*1501,317*96*511*120853*1,415*
Net cash from financing activities(14)*(4,242)(7,845)*362*(42,855)*947(14,663)*(19,977)*(28,447)*(23,144)(23,432)*(17,583)*
Net change in cash10,137*(11,791)6,821*11,080*(1,492)*(18,780)10,108*9,254*9,074*(15,392)(6,389)*1,252*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Bioventus30,709142,44220,658*not reported— 10-QSep 26, 2026
Treace Medical Concepts12,61045,376(4,698)*65.0M9.7 quarters 10-QJun 30, 2026
SS Innovations International13,647not reported(4,235)*200.4M3.2 quarters 10-QJun 30, 2026
SANUWAVE Health9,3769,739425*8.6M— 10-QJun 30, 2026
Cerus16,35057,7143,007*202.0M— 10-QSep 30, 2026
NeuroPace12,53822,826(3,903)*34.3M13.2 quarters 10-QJun 30, 2026
Electromed20,45019,417*2,994*8.4M— 10-KJun 30, 2026
Tactile Systems Technology75,11091,85811,978*22.4M— 10-QSep 30, 2026
Orasure Technologies160,58230,639(9,921)*69.0M16.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.